kwic
observed
observed
right
off
ON
431
1
100
500
strict
ELIZA cgi-bash version rev. 1.90
- Medical English LInking keywords finder for the PubMed Zipped Archive (ELIZA) -
return
kwic search for observed out of >500 occurrences
392826 occurrences (No.45 in the rank) during 5 years in the PubMed. [cache]
--- ABSTRACT ---
--- ABSTRACT END ---
[frequency of next (right) word to observed]
392826 occurrences (No.45 in the rank) during 5 years in the PubMed. [cache]
| 431) Although a synergistic effect of combined ZOL and meloxicam was not observed, combination therapy was well-tolerated and may be useful in the clinical management of bone-invasive feline OSCC. |
| PMID:23651067 DOI:10.1111/vco.12037 |
| 2015 Veterinary and comparative oncology |
| * Combined zoledronic acid and meloxicam reduced bone loss and tumour growth in an orthotopic mouse model of bone-invasive oral squamous cell carcinoma. |
| - Oral squamous cell carcinoma (OSCC) is common in cats and humans and invades oral bone. We hypothesized that the cyclooxygenase (COX)-2 inhibitor, meloxicam, with the bisphosphonate, zoledronic acid (ZOL), would inhibit tumour growth, osteolysis and invasion in feline OSCC xenografts in mice. Human and feline OSCC cell lines expressed COX-1 and COX-2 and the SCCF2 cells had increased COX-2 mRNA expression with bone conditioned medium. Luciferase-expressing feline SCCF2Luc cells were injected beneath the perimaxillary gingiva and mice were treated with 0.1 mg kg(-1) ZOL twice weekly, 0.3 mg kg(-1) meloxicam daily, combined ZOL and meloxicam, or vehicle. ZOL inhibited osteoclastic bone resorption at the tumour-bone interface. Meloxicam was more effective than ZOL at reducing xenograft growth but did not affect osteoclastic bone resorption. Although a synergistic effect of combined ZOL and meloxicam was not observed, combination therapy was well-tolerated and may be useful in the clinical management of bone-invasive feline OSCC. |
[
right
kwic]
(1)155  in |
(9)9 on |
(17)4 a |
(25)2 data |
| (2)48 *null* | (10)8 by |
(18)4 during |
(26)2 experimentally |
| (3)36 that |
(11)8 to |
(19)4 the |
(27)2 reduction |
| (4)19 for |
(12)8 when |
(20)3 variation |
(28)2 significant |
| (5)18 at |
(13)6 among |
(21)2 as |
(29)2 through |
| (6)16 between |
(14)6 following |
(22)2 changes |
(30)2 throughout |
| (7)11 with |
(15)5 after |
(23)2 clinical |
(31)2 up |
| (8)9 and |
(16)5 from |
(24)2 compared |
(32)2 using |
add keyword
--- WordNet output for observed ---